BETAHISTINE 24 MG — DIN 02466457
BETAHISTINE HYDROCHLORIDE : 24 MG · SANIS HEALTH INC · TABLET · wholesale supply in Canada
Health Canada status: DORMANT
What is BETAHISTINE?
BETAHISTINE 24 MG contains BETAHISTINE HYDROCHLORIDE : 24 MG. It is listed in the Health Canada Drug Product Database under DIN 02466457, held by SANIS HEALTH INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as dormant, status dated 23-Jul-2026. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A). This DIN is not currently being marketed in Canada, so it is sourced to order where a compliant route exists rather than held in stock.
What is BETAHISTINE used for?
BETAHISTINE (betahistine dihydrochloride) is indicated for: reducing the episodes of recurrent vertigo associated with Ménière's disease.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Betahistine cost around the world?
Betahistine is listed on 4 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Greece publishes a producer price (ex-factory); Morocco publishes a PPV (public price); South Africa publishes a single exit price. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Greece | producer price (ex-factory) | 11 | 11 | EUR███.██ |
| Morocco | PPV (public price) | 4 | 5 | MAD███.██ |
| United Kingdom | hospital | 3 | 3 | GBP███.██ |
| South Africa | single exit price | 3 | 3 | ZAR███.██ |
22 pack listings across 21 brand entries and 4 price bases, refreshed 05 Sep 2026. Ranges span every Betahistine pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Betahistine in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
13 holders have a Canadian DIN containing Betahistine, across 33 DINs, of which 17 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| AURO PHARMA INC | 3 | 3 | AURO-BETAHISTINE | Sourceable in Canada |
| MANTRA PHARMA INC | 3 | 3 | M-BETAHISTINE | Sourceable in Canada |
| MINT PHARMACEUTICALS INC | 3 | 3 | MINT-BETAHISTINE | Sourceable in Canada |
| NORA PHARMA INC | 3 | 3 | NRA-BETAHISTINE | Sourceable in Canada |
| TEVA CANADA LIMITED | 3 | 3 | TEVA-BETAHISTINE | Sourceable in Canada |
| BGP PHARMA ULC | 2 | 2 | SERC | Sourceable in Canada |
| APOTEX INC | 3 | 0 | APO-BETAHISTINE | No marketed DIN |
| SANIS HEALTH INC | 3 | 0 | BETAHISTINE | No marketed DIN |
| SURAX HEALTHCARE INC | 3 | 0 | BETAHISTINE | No marketed DIN |
| ACTAVIS PHARMA COMPANY | 2 | 0 | ACT BETAHISTINE | No marketed DIN |
| PHARMASCIENCE INC | 2 | 0 | PMS-BETAHISTINE | No marketed DIN |
| SOLVAY PHARMA INC | 2 | 0 | SERC - TAB 4MG, SERC 8 MG | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 24 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | BETAHISTINE (betahistine dihydrochloride) 8 mg, 16 mg and 24 mg tablets contain 8 mg, 16 mg and 24 mg of betahistine dihydrochloride respectively. BETAHISTINE (betahistine dihydrochloride) tablets are available as follows: 8 mg tablets: White to almost white, round, flat-faced, bevelled-edge tablets, engraved "N" on one side and "8" on the other side. 16 mg tablets: White to almost white, round, biconvex, scored tablets, engraved "N" on one side and "16" on the scored side. 24 mg tablets: White to almost white, round, biconvex, scored tablets, engraved "N" on one side and "24" on the scored side. BETAHISTINE (betahistine dihydrochloride) 8 mg, 16 mg and 24 mg tablets are available in bottles of 100 tablets and 16 mg and 24 mg tablets are available in blisters of 100 tablets. |
| Storage | Store tablets at controlled room temperature (15-30°C) and protect from exposure to heat and moisture. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Substance and classification
| Active substance | Betahistine |
|---|---|
| ATC code | N07CA01 |
| AHFS class | 28:92.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02466457 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2466457 |
| Brand name | BETAHISTINE |
| Generic / active ingredient | BETAHISTINE HYDROCHLORIDE : 24 MG |
| Market authorization holder | SANIS HEALTH INC |
| Health Canada schedule | Prescription |
| ATC code | N07CA01 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N07CA |
| Current status | DORMANT |
| Status date | 23-Jul-2026 |
| Original market date | 2018-03-07 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
The usual daily dosage range is 24-48 mg administered orally in divided doses. Three Times Daily Dosing: 8 mg tablets: 1 to 2 tablets three times daily. 16 mg tablets: ½ to 1 tablet three times daily. Twice Daily Dosing 24 mg tablets: 1 tablet twice daily. Missed Dose If a dose is missed, the missed dose should not be taken. The next dose should be taken at the usual time. A double dose should never be taken to make up for a forgotten dose. For management of a suspected drug overdose, contact your regional Poison Control Centre. A few overdose cases (up to 640 mg), with mild to moderate symptoms of nausea, dry mouth, dyspepsia, abdominal pain and somnolence have been reported. Presumably, more serious complications (e.g. convulsion, pulmonary or cardiac complications) may occur in cases of intentional overdose of BETAHISTINE (betahistine dihydrochloride) above 640 mg, especially in combination with other overdosed drugs. Standard overdose protocol / supportive measures should be followed.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
BETAHISTINE is contraindicated in: • patients with known hypersensitivity to betahistine or to any of the tablet constituents. For a complete listing, see the DOSAGE FORMS, COMPOSITION AND PACKAGING section. • patients with peptic ulcer and in patients with a history of this condition (see WARNINGS AND PRECAUTIONS, Gastrointestinal). • patients with pheochromocytoma.
Warnings and precautions
Respiratory Although clinical intolerance to betahistine dihydrochloride tablets has been shown in a relatively few patients with bronchial asthma, caution should be exercised when giving the product to asthmatic patients. Gastrointestinal Several patients with a history of peptic ulcer have experienced an exacerbation of symptoms while using betahistine dihydrochloride tablets. Although experiments in animals and in humans have shown that the gastrointestinal side effects associated with betahistine dihydrochloride are not related to gastric acid production, BETAHISTINE is contraindicated in the presence of patients with peptic ulcer and in patients with a history of this condition. Pregnant Women The safety of betahistine dihydrochloride in human pregnancy has not been established. Animal studies are insufficient with respect to effects on pregnancy, embryonal / foetal development, parturition and postnatal development. The potential risk for humans is unknown. Betahistine dihydrochloride should not be used during pregnancy unless the potential benefits to the mother outweigh the potential risk to the fetus. Nursing Women There are no clinical studies of the excretion of betahistine dihydrochloride into human milk. Betahistine accumulates in the milk of lactating rat dams.The importance of the drug to the mother should be weighed against the benefits of nursing and the potential risks for the child. Effect on Ability to Drive and Use Machines Although not studied in patients with Ménière's disease, in clinical studies using normal healthy volunteers without Ménière's disease, 72 mg of betahistine dihydrochloride taken three times daily for three days, had no or negligible effects on driving skills in a driving task. However, Ménière's disease itself can negatively affect the ability to drive and use machines.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
17 of 33 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| AURO-BETAHISTINE | 24 MG | TABLET | AURO PHARMA INC | MARKETED | 02449161 |
| AURO-BETAHISTINE | 8 MG | TABLET | AURO PHARMA INC | MARKETED | 02449145 |
| AURO-BETAHISTINE | 16 MG | TABLET | AURO PHARMA INC | MARKETED | 02449153 |
| M-BETAHISTINE | 8 MG | TABLET | MANTRA PHARMA INC | MARKETED | 02519682 |
| M-BETAHISTINE | 16 MG | TABLET | MANTRA PHARMA INC | MARKETED | 02519690 |
| M-BETAHISTINE | 24 MG | TABLET | MANTRA PHARMA INC | MARKETED | 02519704 |
| MINT-BETAHISTINE | 8 MG | TABLET | MINT PHARMACEUTICALS INC | MARKETED | 02538121 |
| MINT-BETAHISTINE | 16 MG | TABLET | MINT PHARMACEUTICALS INC | MARKETED | 02538148 |
| MINT-BETAHISTINE | 24 MG | TABLET | MINT PHARMACEUTICALS INC | MARKETED | 02538156 |
| NRA-BETAHISTINE | 8 MG | TABLET | NORA PHARMA INC | MARKETED | 02544911 |
2 · Same class — other molecules in ATC N07CA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Betahistine | ACT BETAHISTINE · APO-BETAHISTINE · AURO-BETAHISTINE · BETAHISTINE · +9 more | 33 | 17 | Yes |
| Flunarizine | FLUNARIZINE · NOVO-FLUNARIZINE - CAP 5MG · SIBELIUM CAP 5MG | 3 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is BETAHISTINE called?
Also recorded in Canada as: BETAHISTINE HYDROCHLORIDE (GLOBAL), SERC (EU), SERC (UK), SERC-8 (IN), VERTIN (IN), BETASERC (EU), AGISERC (GLOBAL), LECTIL (EU), VERUM (EU), VESTIBO (EU), BETAHISTINE DIHYDROCHLORIDE (UK).
The same molecule, Betahistine, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| SERC | Latin | Morocco |
| VERTIS | Latin | Morocco |
| Zygovert | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
This DIN is dormant — it holds a Health Canada authorization but is not currently being marketed in Canada, so it cannot simply be ordered from Canadian stock. Where a patient need exists, supply may be possible through exceptional importation or the Special Access Programme, subject to Health Canada's requirements and the prescriber's application. Nexara can advise on the route and on marketed alternatives.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.